SCHEMBL7925816

SCHEMBL7925816

Cc1ccc(S(=O)(=O)OC[C@@H](O)Cc2ccccc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
CA2 P00918 1/20 0.45
CA7 P43166 1/20 0.45
POLB P06746 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
CA12 O43570 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
ATM Q13315 1/20 0.43
CA9 Q16790 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
CTSL P07711 1/20 0.42
LMNA P02545 1/20 0.42
DHODH Q02127 1/20 0.41
MCHR1 Q99705 1/20 0.41
STAT3 P40763 1/20 0.41
ALDH1A1 P00352 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7933300 1.00 GAA (0.49) GAACA2CA7POLBPPARG
SCHEMBL21378598 1.00 GAA (0.49) GAACA2CA7POLBPPARG
SCHEMBL2076249 0.86 ALDH1A1 (0.51) GAAPOLBBCHEACHECA12
SCHEMBL2076248 0.86 ALDH1A1 (0.51) GAAPOLBBCHEACHECA12
SCHEMBL2076247 0.86 ALDH1A1 (0.51) GAAPOLBBCHEACHECA12
SCHEMBL25428625 0.86 GAA (0.47) GAACA2CA7PPARGPPARA
SCHEMBL4756032 0.85 CA2 (0.47) GAACA2CA7BCHEACHE
SCHEMBL17460433 0.85 CA2 (0.47) GAACA2CA7BCHEACHE
SCHEMBL4020804 0.85 CA1 (0.50) GAACA2CA7POLBCA9
SCHEMBL4020810 0.85 CA1 (0.50) GAACA2CA7POLBCA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130184313-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-07-18 US disclosed
US-8445684-B2 Nicotinic acetylcholine receptor ligands and the uses thereof PsycoGenics Inc. (US) 2013-05-21 US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 US disclosed
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INC. (US) 2010-06-17 US disclosed
WO-2010045212-A2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF PSYCHOGENICS, INCSTATUTS (US) 2010-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152450-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF CHRNG, CHRNA5, CHRNA2 GAA 3761/4885CA2 3220/4885CA7 4220/4885
US-20130184313-A1 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF CHRNG, CHRNA5, CHRNA2 GAA 3761/4885CA2 3220/4885CA7 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.